October 8, 2026
Notice Regarding MolDX: Biomarker Testing for Risk Stratification in DCIS (DL40246)
Medicare Administrative Contractors (MACs) take significant care and consider all the available evidence relevant to the local coverage determinations (LCDs) they publish. Given the numerous Comments received related to current and impending clinical evidence to be considered, this MAC has decided to retire the following draft LCD DL40246: MolDX: Biomarker Testing for Risk Stratification in DCIS.
As such, the Contractor Advisory Committee Meeting, scheduled for October 13, 2026, will be canceled. Any further updates on this topic will be provided on our website.

